[Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Record ID 32018000826
Original Title: Caplacizumab (erworbene thrombotisch-thrombozytopenische Purpura, Jugendliche ab 12 Jahren) – Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V
Project Status: Completed
Year Published: 2020
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Purpura, Thrombocytopenic
  • Purpura, Thrombotic Thrombocytopenic
  • Fibrinolytic Agents
  • Single-Domain Antibodies
  • von Willebrand Factor
  • Drug Therapy
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.